Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFβ-induced lung fibrosis

Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFβ-induced lung fibrosis

Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease of unknown etiology. Currently, pirfenidone and nintedanib are the only FDA-approved drugs for the treatment of IPF and are now the standard of care. This is a significant step in slowing down the progression of the...

Full description

Bibliographic Details
Main Authors: Afshin Ebrahimpour, Manisha Ahir, Min Wang, Anil G. Jegga, Mark D. Bonnen, N. Tony Eissa, Sydney B. Montesi, Ganesh Raghu, Yohannes T. Ghebre
Format: Article
Language:English
Published: Nature Portfolio 2022-11-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-24985-x

Similar Items

Similar Items